Skip to main content
. 2018 Mar 2;9(3):349. doi: 10.1038/s41419-018-0387-2

Fig. 2. DNA vs. mRNA quantitative PCR results.

Fig. 2

The figure displays the kinetics of the leukemic cell burden in patients treated with Imatinib mesylate after the diagnosis in early chronic phase. (I-P) The panels show the percentage of cancer cells (BCR-ABL1/BCR) as measured by gDNA qPCR (⊗DNA values, solid line) and RT–qPCR (▲RNA values, dashed line) in patients 9 to 16